As of July, how many patients had received convalescent plasma for COVID-19 treatment?

As of July, how many patients had received convalescent plasma for COVID-19 treatment?

• A. 10,000 patients
• B. 15,000 patients
• C. 20,000 patients
• D. 25,000 patients

Answer: (D)

The answer indicates that by July, a total of 25,000 patients had received convalescent plasma as a treatment for COVID-19. This choice reflects the ongoing efforts and research surrounding convalescent plasma therapy, which involves using the blood plasma from individuals who have recovered from the virus to treat those currently infected. This approach gained significant attention during the pandemic as a potential therapeutic option. The increasing number of patients treated with convalescent plasma highlights the medical community's efforts to explore multiple avenues for effective COVID-19 treatments. The number chosen reflects a substantial commitment to administering this treatment, indicating that it was being widely utilized. In contrast, the other numerical options represent lower figures that may not encompass the full scope of treatment efforts that were documented for the broader patient population receiving this type of therapy.

The answer indicates that by July, a total of 25,000 patients had received convalescent plasma as a treatment for COVID-19. This choice reflects the ongoing efforts and research surrounding convalescent plasma therapy, which involves using the blood plasma from individuals who have recovered from the virus to treat those currently infected.

This approach gained significant attention during the pandemic as a potential therapeutic option. The increasing number of patients treated with convalescent plasma highlights the medical community's efforts to explore multiple avenues for effective COVID-19 treatments. The number chosen reflects a substantial commitment to administering this treatment, indicating that it was being widely utilized.

In contrast, the other numerical options represent lower figures that may not encompass the full scope of treatment efforts that were documented for the broader patient population receiving this type of therapy.